<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512889</url>
  </required_header>
  <id_info>
    <org_study_id>06-250</org_study_id>
    <nct_id>NCT00512889</nct_id>
  </id_info>
  <brief_title>Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma</brief_title>
  <official_title>A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight
      infections and cancer. These CTL can be manipulated in the laboratory so that they can target
      an individual's cancer.

      PURPOSE: This early phase trial is studying the feasibility and side effects of intravenous
      infusions of CTL generated in the laboratory. To produce the CTL, the study participant's own
      immune cells are collected by a procedure called a leukapheresis. The cells then undergo
      laboratory processing for three weeks. Part of this processing includes mixing the patients
      immune cells with a new kind of cell that has some extra genes added to it. These extra genes
      are to &quot;teach&quot; the participant's own immune cells to become anti-tumor CTL that can attack
      the melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DETAILED OUTLINE: This is an early phase pilot/feasibility trial.

      Study subjects will be sequentially accrued to three cohorts. Cohorts 1 and 2 will evaluate
      the safety and feasibility of infusing two different doses of CTL.

        -  Participants in all cohorts will undergo two CTL infusions 5 weeks apart.

        -  Procedures performed during the trial will include physical examinations, laboratory
           tests, delayed hypersensitivity testing, and skin biopsies.

        -  Between 5 and 8 days after the first CTL infusion, a biopsy or excision of a melanoma
           lesion may be performed.

        -  Three leukapheresis procedures will be performed: two to collect peripheral blood for
           CTL production and one for research purposes at the end of the clinical trial.

        -  Radiology tests (including CT scans) will be performed prior to infusion and about 4-5
           weeks after the second CTL infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define the feasibility of generating large doses of MART1/Melan-A specific CTL following leukapheresis in this patient population</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the toxicity of two dose levels of adoptively transferred MART1/Melan-A specific CTL lines</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the feasibility of combining the infusion of MART1/Melan-A specific CTL with the administration of GM-CSF +/- radiotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the toxicity of combining the infusion of MART1/Melan-A specific CTL with the administration of GM-CSF +/- radiotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate function, phenotype, and trafficking of infused CTL.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different dose of CTL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different dose of CTL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CTL with GMCSF +/- radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Use of an artificial antigen presenting cell (aAPC) to generate CTL</intervention_name>
    <description>A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Irradiation of cutaneous tumor lesion</intervention_name>
    <description>Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic melanoma: Either unresectable Stage III or any Stage IV

          -  ECOG of 0 or 1

          -  HLA-A*0201 haplotype

          -  Baseline tumor biopsy MART1/Melan-A expression present (in &gt;10% of tumor cells)

          -  Patient provides consent for all required biopsies

          -  Adequate intravenous access for leukapheresis

          -  Absolute lymphocyte count &gt;500/ul at least once within 30 days of leukapheresis

          -  Life expectancy greater than 4 months in the opinion of the study clinician

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Administration of systemic corticosteroids within 28 days of planned leukapheresis

          -  Administration of cytotoxic chemotherapy or anti-tumor immunotherapy within 28 days of
             planned leukapheresis

          -  Administration of radiotherapy within 28 days of planned leukapheresis with the
             exception of subjects accrued to Cohort 3

          -  Active autoimmunity requiring systemic immunosuppressive therapy

          -  HIV infection

          -  Previous enrollment on this protocol and infusion of MART1/Melan-A CTL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Butler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27;3(80):80ra34. doi: 10.1126/scitranslmed.3002207.</citation>
    <PMID>21525398</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Marcus O. Butler, MD</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>CTL</keyword>
  <keyword>MART-1</keyword>
  <keyword>Melan-A</keyword>
  <keyword>artificial APC</keyword>
  <keyword>melanoma</keyword>
  <keyword>metastatic melanoma</keyword>
  <keyword>adoptive immunotherapy</keyword>
  <keyword>adoptive cell transfer</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

